Triptazine, 5 mg 50 pcs.

Triftazine is a neuroleptic from the group of phenothiazine piperazine derivatives. It has pronounced antipsychotic and antiemetic effects, has a-adrenolytic and weak anticholinergic and sedative effects.

The neuroleptic effect is combined with a moderate stimulant effect (in low doses). Triptazine has a pronounced and prolonged effect on productive psychotic symptoms (hallucinations, delirium). Causes extrapyramidal disorders.

Pharmacokinetics:

It is well absorbed from the gastrointestinal tract and from parenteral administration sites.

The time to reach maximum concentration when administered intramuscularly is 1 -2 hours.

The binding to plasma proteins is 95% (therefore poorly dialyzed).

Metabolized in the liver, half-life 15-30 h, most metabolites are pharmacologically inactive.

Extracted by the kidneys and with the bile. Triptazine penetrates the placenta.

Indications

Active ingredient

Composition

1 coated tablet contains:

the active ingredient:

trifluoperazine hydrochloride 5 mg

excipients:

refined sugar,

potato starch,

p> aerosil,

calcium stearate,

gelatin,

p> magnesium carbonate basic,

indigo carmine,

polyvinylpyrrolidone,

wax,

titanium dioxide,

talc.

How to take, the dosage

Triftazine is taken orally, after meals.

The doses are chosen individually according to the severity of the condition; for dose titration, it is advisable to use dosage forms with the appropriate (lower) dosage. When the maximum therapeutic effect is achieved, the dose is gradually reduced to a maintenance dose. Usually for the treatment of anxiety states adults are prescribed 1 mg 2 times a day. For patients with psychotic disorders, 2-5 mg 2 times daily is started. For optimal therapeutic effect, the dose is gradually increased to 15-20 mg/day, divided into 2-3 doses, the maximum daily dose is 40 mg.

The desired therapeutic effect and improvement of the patient’s condition usually requires 2-3 weeks.

Children 6-12 years old with psychotic disorders are prescribed 1 mg 1 -2 times a day, if necessary this dose can be increased to 4mg/day. The dose for children over 12 years of age is 5-6 mg per day, divided into several doses.

In adults with vomiting – 1-2 mg 2 times a day. For elderly patients, the initial dose of the drug should be reduced by half.

Interaction

In concomitant use of Triptazine with other drugs with CNS depressant effect (general anesthetics, narcotic analgesics, ethanol (alcohol) and drugs containing it, barbiturates, tranquilizers, etc.) an increase in CNS depression and respiratory depression are possible.

A prolonged combination with analgesics and antipyretics is undesirable – hyperthermia may develop;

with tricyclic antidepressants, maprotiline or monoamine oxidase inhibitors (MAOIs) – increased risk of neuroleptic malignant syndrome; with anticonvulsants – possible lowering of seizure threshold; with drugs for the treatment of hyperthyroidism – increased risk of agranulocytosis; with other drugs causing extrapyramidal reactions – increased frequency and severity of extrapyramidal disorders;

with hypotensive drugs – pronounced orthostatic hypotension possible; with ephedrine – possible weakening of vasoconstrictor effect of ephedrine. During treatment with Triptazine the administration of epinephrine (adrenaline) should be avoided because the effect of epinephrine may be distorted, which may lead to a drop in blood pressure. Antiparkinsonian effects of levodopa are reduced by blocking dopamine receptors. Trifetazine can inhibit the effects of amphetamines, clonidine, guanethidine. Triptazine enhances the anticholinergic effects of other drugs, and the antipsychotic effect of the neuroleptic may be reduced.

The concomitant use of Triftazine with prochlorperazine may cause prolonged loss of consciousness.

Combination with lithium preparations increases the risk of extrapyramidal complications. Trifetazine may mask some ototoxicity manifestations (tinnitus, dizziness) of drugs with ototoxic effects (e.g., antibiotics). Other hepatotoxic drugs increase the risk of hepatotoxicity. Antacids containing Al3+ and Mg2+ reduce absorption of triftazine.

Special Instructions

Blood pressure, pulse rate, and liver, kidney, and blood function should be monitored regularly during treatment.

Alcohol should be avoided during treatment!

During treatment, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Nervous system disorders: drowsiness, dizziness, insomnia, phenomena of mental indifference (with prolonged use), delayed reactions to external stimuli. Triptazine use is often accompanied by extrapyramidal disorders (dyskinesia, akinetorigid phenomena, akathisia, hyperkinesias, tremor, vegetative disorders), in single cases, convulsions. Antiparkinsonian agents – tropacin, trihexyphenidyl (cyclodol), etc. – are used as correctors. Dyskinesias (paroxysmal cramps of muscles of the neck, tongue, floor of the mouth, oculogyric crises) are stopped by caffeine-benzoate sodium (2 ml 20% solution subcutaneously) and atropine (1 ml 0.1% solution subcutaneously).

Long-term administration may lead to the development of tardive dyskinesia, less often to malignant neuroleptic syndrome.

Sensory organs: paresis of accommodation, with prolonged use – retinopathy, clouding of the lens and cornea.

Hyrogenital system disorders: urinary retention, decreased potency, frigidity, decreased libido, ejaculation disorders, priapism, oliguria.

Endocrine system disorders: hypo- or hyperglycemia, glucosuria, amenorrhea, hyperprolactinemia, dysmenorrhea, galactorrhea, breast swelling or pain, gynecomastia, weight gain.

Digestive system disorders: dry mouth, decreased appetite, constipation, bulimia, nausea, vomiting, diarrhea, gastralgia, cholestatic jaundice.

Sensory organs: visual impairment – accommodation paresis (at the beginning of treatment), retinopathy, lens and corneal opacity.

Laboratory parameters: thrombocytopenia, lympho- and leukopenia, increased blood clotting, anemia, agranulocytosis (more often in 4-10 weeks of treatment), pancytopenia, eosinophilia – less often than in other phenothiazines, false positive pregnancy tests.

Cardiovascular system disorders: tachycardia, decreased arterial pressure (including orthostatic hypotension) especially in elderly patients and persons suffering from alcoholism, cardiac rhythm disorders, QT interval prolongation, decrease or inversion of T wave. Allergic reactions: skin rash, urticaria, angioedema (less frequent than in other phenothiazines).

Others: pigmentation of the skin and conjunctivae, discoloration of the sclerae and cornea, decreased tolerance to high temperatures (up to development of heat stroke), melanosis.

Local reactions: with intramuscular injection infiltrates may occur; with contact dermatitis if liquid forms come into contact with skin.

Overdose

Symptoms: Areflexia or hyperreflexia, blurred vision, cardiotoxic effects (arrhythmia, heart failure, decreased blood pressure, shock, tachycardia, QRS complex changes, ventricular fibrillation, cardiac arrest), neurotoxic effects including agitation, confusion, seizures, disorientation, drowsiness, stupor or coma; Mydriasis, dry mouth, hyperpyrexia or hypothermia, muscle rigidity, vomiting, pulmonary edema, or respiratory depression.

The treatment is symptomatic: for arrhythmia, intravenous (IV) phenytoin 9-11 mg/kg; for heart failure, cardiac glycosides; for marked decreases in blood pressure, IV fluids or vasopressors such as norepinephrine, phenylephrine (avoid administration of alpha- and beta-adrenomimetics such as epinephrine, because of possible paradoxical decrease in blood pressure, due to blockade of alpha-adrenoreceptors by trifluoperazine), in convulsions – diazepam (avoid prescription of barbiturates, due to possible subsequent CNS and respiratory depression), in parkinsonism – diphenyltropine, diphenhydramine. Control of cardiovascular system function for at least 5 days, CNS function, respiration, body temperature measurement, consult a psychiatrist. Dialysis is ineffective.